Humacyte, Inc.

Humacyte, Inc. completed its business combination with Alpha Healthcare Acquisition Corp III, the SPAC that traded under the ticker AHAC and was sponsored by Alpha Healthcare Advisors LLC, a firm with a focused healthcare investment mandate. Alpha Healthcare Acquisition Corp III conducted its initial public offering in 2021 and targeted opportunities in the life sciences and biotechnology sector. Humacyte, a clinical-stage regenerative medicine company headquartered in Durham, North Carolina, develops bioengineered human acellular vessels designed for vascular repair and reconstruction. The company began trading on Nasdaq under the ticker HUMA following the closing of the de-SPAC transaction in September 2021. The June 2023 Form 8-K represents one of the company's post-merger periodic filings with the SEC. Readers seeking full deal history, filing timelines, and investor analytics on AHAC and comparable healthcare SPACs can sign up for complete access at SpacDesk.